# Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081

> **NCT04608955** · PHASE2 · COMPLETED · sponsor: **Shanghai Jiatan Pharmatech Co., Ltd** · enrollment: 99 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** WX-081
- **DRUG:** Bedaquiline
- **DRUG:** Standard treatment
- **DRUG:** Multi-drug background treatment (MBT)

## Key facts

- **NCT ID:** NCT04608955
- **Lead sponsor:** Shanghai Jiatan Pharmatech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-16
- **Primary completion:** 2022-04-13
- **Final completion:** 2022-04-13
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608955, "Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04608955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*